Genovis launches FabRICATOR® 96-well plate for high throughput applications

Genovis is launching the FabRICATOR 96-well plate at the 2012 ASMS conference
(May 19-24) in Vancouver, Canada, and the ADC Summit 2012 (May 23-24) conference
in London.
The FabRICATOR 96-well plate is standard format and fits most robotic systems.
Each well in the plate contains a small quantity of freeze-dried high-quality
enzyme for rapid and complete antibody subunit fragmentation of 96 samples. The
plates are sealed with aluminum foil that allows for pipette tip penetration.
Antibodies or Fc-fusion proteins can be added directly to the well for
convenient rapid processing.

“With this product we believe we can simplify the workflow for our customers
when it comes to robust assays and multiple sample handling. This product is an
excellent example of strategic R&D efforts at Genovis. We continually focus on
new products that can save time, simplify use and improve analysis quality for
the end user,” says Fredrik Olsson, COO of Genovis.

FabRICATOR®

Genovis has developed the FabRICATOR enzyme, which can rapidly generate F(ab’)2
fragments from IgG molecules. FabRICATOR is a recombinant and modified IdeS
enzyme* that cleaves IgG in a well-defined site just below the hinge region,
generating one intact F(ab ́)2 and two residual Fc fragments. The yield and
speed of the reaction are exceptionally high and the enzyme does not generate
any additional fragmentation.

*IdeS is a highly substrate specific cysteine protease originating from
Streptococcus pyogenes and is patent pending. FabRICATOR® is a registered
trademark for recombinant IdeS.
For more information, please contact: Fredrik Olsson, COO, Genovis AB Tel: 4646
-101235 fredik.olsson@genovis.com (sarah.fredriksson@genovis.com)
ABOUT GENOVIS

Genovis develops and sells innovative technologies from two unique product
portfolios. The first includes enzymes that facilitate development and quality
control for applications such as antibody-based drugs. The products launched to
date are aimed at customers who work with development of drugs, new diagnostic
methods and basic research.

The second consists of nanotechnology in new contrast agents and focuses on
design, production and characterization of nanostructures as contrast agents in
medical imaging. The nanostructures and methods that Genovis focuses on can also
be used as carriers of various substances in the development of new drug
delivery methods. The projects are mainly in-house, but also include
collaborations with research groups, including at Lund University.

Genovis shares are listed on the First North OMX Nordic Exchange and Thenberg
Fondkommission is our certified advisor.